Abstract:
Applicants have discovered previously uncharacterized genes and proteins that are involved in iron transport and/or metabolism. Accordingly, the present invention provides proteins involved in iron transport and/or metabolism and polynucleotides encoding those proteins. The present invention also provides expression cassettes containing the polynucleotides. The present invention also provides cells containing the expression cassettes, polypeptides, and/or polynucleotides of the invention.
Abstract:
Applicants have discovered previously uncharacterized genes and proteins that are involved in iron transport and/or metabolism. Accordingly, the present invention provides proteins involved in iron transport and/or metabolism and polynucleotides encoding those proteins. The present invention also provides expression cassettes containing the polynucleotides. The present invention also provides cells containing the expression cassettes, polypeptides, and/or polynucleotides of the invention.
Abstract:
Applicants have discovered previously uncharacterized genes and proteins that are involved in iron transport and/or metabolism. Accordingly, the present invention provides proteins involved in iron transport and/or metabolism and polynucleotides encoding those proteins. The present invention also provides expression cassettes containing the polynucleotides. The present invention also provides cells containing the expression cassettes, polypeptides, and/or polynucleotides of the invention.
Abstract:
The present invention provides nucleic acid molecules unique to M. paratuberculosis. The invention also provides the polypeptides encoded by the M. paratuberculosis- specific nucleic acid molecules of the invention, and antibodies having specific binding affinity for the polypeptides encoded by the paratuberculosis- specific nucleic acid molecules. The invention further provides for methods of detecting M. paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies of the invention. The invention additionally provides methods of preventing a M. paratuberculosis infection in an animal.
Abstract:
The present invention provides nucleic acid molecules unique to L. intracellularis. The invention also provides the polypeptides encoded by the L. intracellularis-specific nucleic acid molecules of the invention, and antibodies having specific binding affinity for the polypeptides encoded by the L. intracellularis-specific nucleic acid molecules. The invention further provides for methods of detecting L. intracellularis in a sample using nucleic acid molecules, polypeptides, and antibodies of the invention. The invention additionally provides methods of preventing a L. intracellularis infection in an animal.
Abstract:
The present invention provides nucleic acid molecules unique to M. paratuberculosis. The invention also provides the polypeptides encoded by the M. paratuberculosis- specific nucleic acid molecules of the invention, and antibodies having specific binding affinity for the polypeptides encoded by the paratuberculosis- specific nucleic acid molecules. The invention further provides for methods of detecting M. paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies of the invention. The invention additionally provides methods of preventing a M. paratuberculosis infection in an animal.
Abstract:
A method for detecting an avian pneumovirus (APV) infection is described that includes the use of an isolated APV polypeptide and/or anti-APV polypeptide antibodies. Antibodies directed to APV polypeptides as well as articles of manufacture that include isolated APV polypeptides and/or anti-APV polypeptide antibodies are also described.
Abstract:
The present invention provides nucleic acid molecules unique to M.paratuberculosis. The invention also provides the polypeptides encoded by the M.paratuberculosis-specific nucleic acid molecules of the invention, and antibodies having specific binding affinity for the polypeptides encoded by the M.paratuberculosis-specific nucleic acid molecules. The invention further provides for methods of detecting M.paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies of the invention. The invention additionally provides methods of preventing a M.paratuberculosis infection in an animal.
Abstract:
Disclosed are foam compositions and processes to form closed-cell tannin-based foams. The foams comprises a continuous polymeric phase defining a plurality of cells, wherein the continuous polymeric phase comprises a tannin-based resin derived from a tannin and a monomer, wherein the monomer comprises furfural, glyoxal, acetaldehyde, 5-hydroxymethylfurfural, acrolein, levulinate esters, sugars, 2,5-furandicarboxylic acid, 2,5-furandicarboxylic aldehyde, urea, difurfural (DFF), furfuryl alcohol, glycerol, sorbitol, lignin, or mixtures thereof, and wherein the plurality of cells comprises a plurality of open-cells and a plurality of closed-cells with an open-cell content measured according to ASTM D6226-5, of less than 50%. The foam composition also comprises a discontinuous phase disposed in at least a portion of the plurality of closed-cells, the discontinuous phase comprising one or more blowing agents.
Abstract:
Disclosed are foam compositions and processes to form closed-cell tannin-based foams. The foams comprises a continuous polymeric phase defining a plurality of cells, wherein the continuous polymeric phase comprises a tannin-based resin derived from a tannin, a first monomer, and a second monomer, wherein the first monomer comprises formaldehyde, paraformaldehyde, furfural, glyoxal, acetaldehyde, 5-hydroxymethylfurfural, acrolein, levulinate esters, sugars, 2,5-furandicarboxylic acid, 2,5-furandicarboxylic aldehyde, urea, difurfural (DFF), or mixtures thereof, and the second monomer comprises furfuryl alcohol, glycerol, sorbitol, lignin, or mixtures thereof, and wherein the plurality of cells comprises a plurality of open-cells and a plurality of closed-cells with an open-cell content measured according to ASTM D6226-5, of less than 50%. The foam composition also comprises a discontinuous phase disposed in at least a portion of the plurality of closed-cells, the discontinuous phase comprising one or more blowing agents.